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What We Think We See, May Be What We Think We Get,
But If We Only Knew
Many practitioners of the fledgling discipline of interven-
tional cardiology may count Charles Dotter, Andreas
Gruntzig, Marcus DeWood (and Selinger and Berg), Peter
Rentrop, and Geoffrey Hartzler among their heroes. What-
ever else each of these individuals did or did not do, for a
moment they had the courage to try something for their
patients that they believed might help and most authorities
of the time “knew” would not (i.e., counterintuitive).
See page 971
At the time each of these individuals attempted a new
procedure:
● To run a vascular dilator over a wire through the
obstructed leg artery of patients tentatively scheduled for
lower extremity amputation (1);
● To take acute myocardial infarction (MI) patients to the
catheterization laboratory and then to emergency bypass
surgery (2,3);
● To inflate a balloon within the lumen of a tight osteal left
anterior descending artery of an awake patient, with
limiting angina (4);
● To try to open occluded arteries in acutely infarcting
patients by using intracoronary nitroglycerin and strep-
tokinase and even a 32/1,000 guide wire (5);
● To take acutely infarcting patients to the catheterization
laboratory to combine steps 2 through 4 by ballooning
fresh thrombotic occlusion (6).
none of these approaches was considered reasonable by most
authorities of the time.
Point one: Had they not dared, there would have been no
subsequent justification for many of the trials that have
facilitated a revolution in the care of acute ST elevation MI.
After Dotter, Judkins, Gruntzig, DeWood, Rentrop,
Hartzler, and many others, as well as their courageous
patients, “got away with it” and some of their patients
appeared to benefit, it then became possible to consider
whether these innovations were real advances, applicable to
a broad range of patients, rather than isolated observations.
With the concomitant developments in epidemiology, bio-
statistics, and the growing discipline of randomized clinical
trials, it became possible to design, conduct, and analyze
trials, ushering in the “reperfusion era” and leading to new
debates, such as the intravenous thrombolytic therapy versus
primary angioplasty debate and whether patients should be
transported for primary angioplasty or have it performed at
centers without on-site surgery, among others. We now
know that reperfusion therapy is the way to treat acute ST
elevation MI, and we know that where an experienced
interventional team is available, primary angioplasty confers
better results than thrombolytic therapy (7–13).
Point two: Biologic and clinical insights are evolutionary,
often requiring revision after new counterintuitive results
are obtained in serial randomized clinical trials.
In the meantime, we have also learned from the hard
work of countless investigators and hundreds of thousands
of brave patients that:
● Stents can treat and prevent occlusive dissection and
acute recoil (13);
● Stents can prevent negative remodeling and recoil,
thereby reducing restenosis (14,15); and
● Stents are associated with improved short- and long-term
outcomes among a variety of subsets, including patients
with a heavy thrombus burden, such as acute ST elevation
MI (16–24).
By the time the multicenter Controlled Abciximab and
Device Investigation to Lower Late Angioplasty Compli-
cations (CADILLAC) trial was completed, a number of
small trials of balloon versus stent in primary angioplasty
had been reported, suggesting better outcomes with stents
(16–24). Table 23 in the 2001 ACC/AHA PCI Guidelines
listed seven trials with a total of nearly 1,000 patients in each
arm (13). The CADILLAC trial confirmed that overall,
stent use was associated with improved outcomes, primarily
as a result of decreased repeat revascularization (25). It
further clarified the antiplatelet therapy evolution, which
has been a parallel and synergistic development. These
results have “fit” into the more generalized “stent revolu-
tion,” which has changed percutaneous intervention more
than anything besides the balloon.
Many clinicians and health care planners have questioned
the need for routine stenting and have proposed a variety of
strategies for “provisional stenting.” Essentially, any effort to
optimize balloon angioplasty without a stent (such as
prolonged inflation or high-pressure inflation) and then
document a stent-like result (such as via quantitative an-
giography or Doppler flow measurements or intracoronary
ultrasound measurements), reserving stenting for those pa-
tients who fail to achieve the stent-like result, qualifies as
“provisional stenting.” The primary motivation for provi-
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sional stenting has been economic; however, it is clear that
depending upon the method of augmenting simple balloon
angioplasty (perfusion balloons, noncompliant balloons) and
documenting the stent-like result (ultrasound probes, flow-
wires), provisional stenting may entail additional costs,
albeit perhaps less than one or more stents.
In addition to economic considerations, many anatomies
do not lend themselves to stent delivery (such as diffusely
diseased, small-caliber, and heavily calcified lesions) or to
adequate stent coverage (such as some bifurcation or sharply
angulated segments or transitions from grafts to much
smaller native coronary segments) or to as favorable long-
term results (bifurcations and small-caliber vessels). When
stents were first released, the most counterintuitive setting
into which to place them might well have been settings with
a heavy thrombus burden. Yet, unstable angina and acute
ST elevation MI patients with angiographic thrombus have
clearly benefited from this technology.
In this issue of the Journal, the CADILLAC trialists (26)
focused on the portion of ST elevation MI patients ran-
domly allocated to balloon only, which met rigorous, core
lab-adjudicated criteria for a stent-like result. The use of a
separate core lab to identify a stent-like angiographic result
after the fact is, in a sense, the best-case analysis for
provisional stenting. Similarly, if a heavy thrombus burden
identifies a particularly unfavorable lesion characteristic for
stenting, then the subset of acute ST elevation MI patients
who got an optimal result with balloon alone should be one
group for which provisional stenting makes the most sense.
The finding that even these patients did worse in the long
run than their routinely stented brethren joins a list of recent
provisional versus routine stenting trials in more favorable
(i.e., less acute and less likely to be clot-rich) patient groups
(27–31). The concordance of the results across a wide
spectrum of pathology is leading many operators to the
conclusion that the optimal strategy is to deploy a stent
wherever there is a flow-limiting lesion that you can reach
and in which you can fully deploy a suitable stent. This may
be oversimplified, but for a patient with acute ST elevation
MI and a thrombotic occlusion that can be opened, one is
likely to get better short- and long-term results with a stent.
I am not sure who would have predicted that, when the
original stent protocol included dextran, heparin, aspirin,
and enough Coumadin to have inpatient hospital stays that
rivaled coronary artery bypass grafting, but I do know I
wasn’t one of them.
Point three: When there is concordance among multiple
large, prospective randomized trials testing the same inter-
vention, it is time to incorporate the results into day-to-day
practice.
When my children were much younger, we often went to
celebrations of our Scottish ancestry called the Highland
Games. At these events, Scots and pseudo-Scots partici-
pated in many curious forms of behavior that members of
earlier generations had devised for their amusement. As we
watched a “caber toss,” one of my sons inquired, “Daddy,
why are these men wearing skirts and throwing a telephone
pole?” Before I could formulate a suitable hypothesis, a
particularly large Scot turned to my son and bellowed,
“Because we donna know any better, laddie.” As it happens,
that is also why we do randomized clinical trials.
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